Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ACP3 | P15309 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 5/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.38 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.38 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.38 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3743555 | 0.98 | PDE2A (0.48) | PDE2AGSK3BCES2CES1ALDH1A1 | |
| SCHEMBL28062297 | 0.84 | PDE2A (0.44) | PDE2AGSK3B | |
| SCHEMBL1046560 | 0.81 | PDE2A (0.50) | PDE2AGSK3BCES2CES1ALDH1A1 | |
| SCHEMBL84043 | 0.80 | PDE2A (0.53) | PDE2ACES2CES1ALDH1A1ACP3 | |
| SCHEMBL3631522 | 0.80 | GSK3B (0.48) | PDE2AGSK3BCES2CES1ALDH1A1 | |
| SCHEMBL4428819 | 0.80 | GSK3B (0.48) | PDE2AGSK3BCES2CES1ALDH1A1 | |
| SCHEMBL1415320 | 0.79 | ESR1 (0.38) | — | |
| SCHEMBL6337812 | 0.79 | NR1H2 (0.53) | — | |
| SCHEMBL7438101 | 0.78 | PDE2A (0.52) | PDE2ACES2CES1ALDH1A1ACP3 | |
| Ammonia Solution, Strong SCHEMBL27642816 | 0.78 | PDE2A (0.52) | PDE2ACES2CES1ALDH1A1ACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102344440-B | Anticoccidial compound for livestock and poultry and preparation method thereof | CHINA ANIMAL HUSBANDRY INDUSTRY CO LTD | 2013-10-30 | — | — | CN | claimed |
| CN-102344440-A | Anticoccidial compound for livestock and poultry and preparation method thereof | CHINA ANIMAL HUSBANDRY INDUSTRY CO LTD | 2012-02-08 | — | — | CN | claimed |
| EP-4692085-A2 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015314-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | TAY THERAPEUTICS LTD (GB) | 2026-01-01 | — | — | US | disclosed |
| EP-4041388-B1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-08-21 | — | — | US | disclosed |
| US-12391641-B2 | Prostaglandin EP4 receptor antagonist compounds | Nxera Pharma UK Limitied (GB) | 2025-08-19 | — | — | US | disclosed |
| CN-113072546-B | Five-membered heteroaromatic derivative and preparation method and application thereof | 广东东阳光药业股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| EP-4558224-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-05-28 | — | — | EP | disclosed |
| CN-119819362-A | Photocatalyst for efficiently catalyzing and synthesizing halogenated aromatic hydrocarbon as well as preparation method and application thereof | 中国石油大学(华东) | 2025-04-15 | — | — | CN | disclosed |
| EP-1541550-A1 | ORGANIC TELLURIUM COMPOUND, PROCESS FOR PRODUCING THE SAME, LIVING RADICAL POLYMERIZATION INITIATOR, PROCESS FOR PRODUCING POLYMER WITH THE SAME, AND POLYMER | Otsuka Chemical Co., Ltd. (JP) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005013985-A1 | TREATMENT FOR ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| CN-1178927-C | Histamine H3 receptor ligands | ��ղķ˹����Ƕ� | 2004-12-08 | — | — | CN | disclosed |
| CN-1296478-A | Histamine H3 receptor ligands | BLACK JAMES FOUNDATION (GB) | 2001-05-23 | — | — | CN | disclosed |
| EP-0718264-B1 | A liquid crystalline compound containing fluorine atom substituted alkyl group(s) and a liquid crystal composition | CHISSO CORP (JP) | 1999-11-17 | — | — | EP | disclosed |
| US-5702641-A | ELECTRICAL AND CHEMICAL STABILITY | CHISSO CORPORATION (JP) | 1997-12-30 | — | — | US | disclosed |
| EP-0718264-A1 | A liquid crystalline compound containing fluorine atom substituted alkyl group(s) and a liquid crystal composition | Chisso Corporation (JP) | 1996-06-26 | — | — | EP | disclosed |
| US-5026729-A | Lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1991-06-25 | — | — | US | disclosed |
| US-4185992-A | Imidazole derivatives | MAY & BAKER LIMITED (GB) | 1980-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391641-B2 | Prostaglandin EP4 receptor antagonist compounds | PTGER1, PTGER4, PTGER2 | PDE2A 358/4885GSK3B 4103/4885CES2 3666/4885 |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, BRD4, PHKB | PDE2A 3114/4885GSK3B 2851/4885CES2 2325/4885 |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, PHKB, BRD4 | PDE2A 3629/4885GSK3B 2014/4885CES2 4265/4885 |
| US-20260015314-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | PTGER4, PTGER1, PTGER3 | PDE2A 628/4885GSK3B 3073/4885CES2 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.